ProCE Banner Activity

TROPiCS-02: Phase III Trial of Sacituzumab Govitecan vs Physician’s Choice Treatment for HR+/HER2- Advanced Breast Cancer

Slideset Download
Conference Coverage
First interim analysis finds that sacituzumab govitecan extends progression-free survival in patients with heavily pretreated metastatic HR-positive/HER2-negative breast cancer.

Released: June 08, 2022

Expiration: June 07, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab